AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
BioMark Diagnostics Inc.
Video analysis: BMKDF
All videosNo video analysis for this stock yet. Request one from our team.
News: BMKDF
BioMark's Metabolomics Platform Captures Global Scientific Interest Following Publications Demonstrating Superior Diagnostic Performance and Cost Efficiency for Liquid Biopsy
Five peer-reviewed studies published in nine months independently confirm high accuracy, robust panel optimization, and commercial viability of BioMark's blood-based assay. Vancouver, British Columbia--(Newsfile Corp. - August 25, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies focused on the early detection of lung cancer through metabolomics, is pleased to announce crucial updates reinforcing the clinical translation of its liquid biopsy technology platform for early non-small cell lung cancer (NSCLC) screening and risk stratification with the publication of two new peer-reviewed scientific papers.
BioMark Diagnostics Endorses Global Call for Equitable Access to Early Screening on 2026 World Lung Cancer Day
Anchored in the 2026 global campaign's core mission of early detection, equitable access to screening, and compassionate patient support, BioMark advances its multi-marker liquid biopsy to ensure no patient is left behind. Vancouver, British Columbia--(Newsfile Corp. - July 31, 2026) - As the global healthcare community unites on August 1st to observe World Lung Cancer Day, BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company") proudly aligns with leading international healthcare organizations demanding equal access to early detection by developing simple, accessible blood testing that empowers patients and physicians with critical diagnostic insights when it matters most.
BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test
BioMark prepares to launch its breakthrough liquid biopsy powered by a newly patented algorithm validated in over 15,000 samples across Quebec, France, and Germany. Vancouver, British Columbia--(Newsfile Corp. - June 23, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies focused on the early detection of lung cancer through metabolomics, today announced a major operational milestone that underscores the strength of Canadian life sciences innovation.
